Zugrel

Composition: Each tablet contains: Active ingredient: prasugrel hydrochloride 10 mg. Excipients: lactose monohydrate, microcrystalline cellulose (Avicel 101), sodium lauryl sulphate, croscarmellose sodium, colloidal silicon dioxide (Aerosil 200), magnesium stearate. Film coating: yellow iron oxide, Opadry II 85G58977 White*, purified water**.

Form: Film-coated tablets

Indications: In combination with acetylsalicylic acid: prevention of atherothrombotic complications (myocardial infarction, stroke, cardiovascular death) in patients with acute coronary syndrome (unstable angina with moderate to high risk, non-ST-elevation myocardial infarction, ST-elevation myocardial infarction) undergoing percutaneous coronary intervention.

Contraindications: Active pathological bleeding; history of transient ischaemic attack or stroke; severe hepatic impairment (Child–Pugh class C); hypersensitivity to prasugrel.

Dosage: Oral administration. The initial single loading dose is 60 mg, followed by a maintenance dose of 10 mg once daily. Patients receiving prasugrel must also take acetylsalicylic acid 75–325 mg daily. In patients weighing <60 kg, consider a maintenance dose of 5 mg.

Side effects: Bleeding, thrombocytopenia, anemia, headache, hypotension, rash, leukopenia, diarrhea, allergic reactions (including anaphylaxis), thrombotic thrombocytopenic purpura.

Interactions: Increased risk of bleeding with NSAIDs, warfarin, anticoagulants, fibrinolytics. Can be used with aspirin, proton pump inhibitors, statins.

Warnings: Use with caution in patients <60 kg, >75 years old, with ulcer disease, surgery, renal/hepatic impairment. Stop at least 7 days before surgery. Platelet transfusion may be required in case of bleeding.

Age restrictions: 18+

Pregnancy: Use only if expected benefit outweighs potential risk. Breastfeeding should be discontinued.

Country of origin: Bangladesh

Manufacturer: Incepta Pharmaceuticals Ltd

Storage conditions: Store below 30°C. Keep out of reach of children.